Europe Intravenous Ibuprofen Market was worth USD 1.82 billion in 2018 and estimated to be growing at a CAGR of 19.23%, to reach USD 4.38 billion by 2023 Ibuprofen is a Non-steroidal anti-Inflammatory drug used to treat pain and fever which can be causative of a disease, trauma or any major operation. In an intravenous form, the drug has a faster onset of action as compared to other forms. IV Ibuprofen is used to manage acute and post-operative pain.
Due to its faster onset of action and fast results, the market is expected to grow at a rapid rate during the forecast period. As it has been approved for paediatric use, the market is further expected to propel. Due to increased incidence of cardiovascular diseases, cancer and fever coupled with shifting trend to non-opoid drugs is further driving the market growth. However, the side effects associated with the use of ibuprofen and the lengthy approval processes are hampering the market growth.
The market for Intravenous Ibuprofen is broadly categorized into age group and indication. By age group the market is divided into adults and paediatrics. Adults are the major consumer base for intravenous ibuprofen. The paediatric segment is expected to grow at a substantial rate. By indication the market is further classified into fever and pain/inflammatory. Fever is projected to be the fastest growing segment. On the basis of geography, the market is analysed under various regions namely U.K, Germany, Italy, France and Spain. Europe is predicted to grow at a substantial rate.
Some of the major companies dominating the market, by their products and services include Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc., CSL Limited, Sandor Medicaids Pvt Ltd., Germin MED, Grifols S.A., Harbin Gloria Pharmaceuticals Co., Ltd., Al Nabeel International Ltd., PT. Soho Industri Pharmasi, and Laboratorios Valmorca, C.A.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Age group
5.1.4 Y-o-Y Growth Analysis, By age group
5.1.5 Market Attractiveness Analysis, By age group
5.1.6 Market Share Analysis, By age group
5.2.4 Y-o-Y Growth Analysis, By Indication
5.2.5 Market Attractiveness Analysis, By Indication
5.2.6 Market Share Analysis, By Indication
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By age group
184.108.40.206 By indication
6.1.4 Market Attractiveness Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By age group
22.214.171.124 By indication
6.1.5 Market Share Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By age group
184.108.40.206 By indication
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Cumberland Pharmaceuticals Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Alveda Pharmaceuticals, Inc.
8.3 CSL Limited
8.4 Sandor Medicaids Pvt Ltd.
8.5 Germin MED
8.6 Grifols S.A.
8.7 Harbin Gloria Pharmaceuticals Co.Ltd.
8.8 Al Nabeel International Ltd.
8.9 Laboratorios Valmorca, C.A.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures